KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Current Leases (2019 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Current Leases for 7 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 11.91% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, up 11.91% year-over-year, with the annual reading at $1.5 million for FY2025, 11.91% up from the prior year.
  • Current Leases for Q4 2025 was $1.5 million at Xenon Pharmaceuticals, up from $1.5 million in the prior quarter.
  • The five-year high for Current Leases was $1.5 million in Q4 2025, with the low at $270000.0 in Q1 2021.
  • Average Current Leases over 5 years is $1.1 million, with a median of $1.3 million recorded in 2023.
  • The sharpest move saw Current Leases fell 19.34% in 2022, then surged 166.19% in 2023.
  • Over 5 years, Current Leases stood at $605000.0 in 2021, then dropped by 19.34% to $488000.0 in 2022, then soared by 166.19% to $1.3 million in 2023, then grew by 5.39% to $1.4 million in 2024, then increased by 11.91% to $1.5 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $1.5 million, $1.5 million, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.